trending Market Intelligence /marketintelligence/en/news-insights/trending/f6CyYR_ZJlooTODA-iYY1w2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Amgen's Repatha passes phase 3 cardiovascular outcomes trial

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Amgen's Repatha passes phase 3 cardiovascular outcomes trial

Amgen Inc.'s phase 3 drug trial for Repatha met its primary composite endpoint and the key secondary composite endpoint.

The trial evaluated whether the drug reduced the risk of cardiovascular events in patients with atherosclerotic cardiovascular disease, the buildup of plaque in arteries. It was designed to assess if treatment with Repatha in combination with statin therapy compared to placebo plus statin therapy reduces cardiovascular events.

The drug trial met the primary endpoint of time to cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization and the key secondary endpoint were the time to cardiovascular death, myocardial infarction or stroke.

In addition, the trial showed a link between lowering LDL cholesterol with Repatha and cardiovascular risk reduction, even in patients previously treated with optimized statin therapy.

No new safety issues were observed.

In addition, a second trial conducted in the patients of the first trial also achieved its primary endpoint, showing that Repatha was non-inferior to placebo for the effect on cognitive function.

Repatha is approved in more than 40 countries, including the U.S., Japan, Canada and in all 28 countries that are members of the EU.